Skip to main content
. 2018 Mar 30;15(6):8582–8588. doi: 10.3892/ol.2018.8402

Figure 1.

Figure 1.

Lower FOXP2 expression predicts a shorter relapse-free survival in patients with breast cancer. Kaplan Meier (A) overall survival and (B) relapse free survival analysis of FOXP2 expression among patients of the whole dataset. Kaplan Meier relapse free survival analysis of FOXP2 expression among patients from the (C) Luminal A, (D) Luminal B, (E) HER-2 and (F) Basal-like subtypes from the kmplot website (kmplot.com/analysis/). HER-2, human epidermal growth factor receptor 2.